Advanced Enzyme Technologies Limited — Investor Meet, 15-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Advanced Enzyme Technologies reported robust Q4 & FY26 financial results. Q4 revenue grew 22% YoY to INR 203.4 Cr, with EBITDA at INR 63.2 Cr (31% margin) and PAT at INR 45.3 Cr (22% margin). Full-year revenue was INR 745.8 Cr, up 17%. All segments saw healthy growth, driven by higher sales in pharma API, biocatalysis, and nutrition. Management is confident in maintaining double-digit growth, focusing on R&D, optimizing capacity, and expanding globally. New R&D center in Nashik will be operational this fiscal year. Despite global challenges and US inflationary pressures, the company aims for steady growth and stable margins, exploring strategic areas like peptides and enhancing shareholder value.